系统综述与荟萃分析:直接抗病毒药物治疗后肝细胞癌复发
该系统综述与荟萃分析检索2015年1月至2017年12月MEDLINE和SCOPUS,纳入24项研究共1820例有肝细胞癌完全缓解史的患者,评估直接抗病毒药物(DAA)治疗后肝细胞癌复发模式。汇总复发率为24.4%(95%CI:18.4%-30.4%),11篇全文研究汇总复发率为21.9%(95%CI:16.2%-28.3%)。作者认为当前数据显示DAA治疗后肝细胞癌复发率可接受,尤其在完全缓解后至少延迟6个月再启动DAA治疗时。
要点
- 24项研究共1820例有肝细胞癌完全缓解史患者,DAA治疗后肝细胞癌复发率0%-59%,汇总估计24.4%(95%CI:18.4%-30.4%)。
- 11篇全文研究汇总肝细胞癌复发率为21.9%(95%CI:16.2%-28.3%)。
- 作者认为若在肝细胞癌完全缓解后至少延迟6个月再启动DAA治疗,复发率尤其可接受。
核心结论
- 当前数据提示DAA治疗后肝细胞癌复发率可接受,尤其在肝细胞癌完全缓解后至少延迟6个月再启动DAA治疗时。
- 描述DAA治疗后肝细胞癌复发的数据质量有限,突出需要高质量前瞻性研究。
研究设计与样本
- 系统综述与荟萃分析,两位评价者检索2015年1月至2017年12月MEDLINE和SCOPUS,纳入评估DAA治疗后肝细胞癌复发模式的研究。
- 采用DerSimonian and Laird随机效应模型计算汇总估计值,研究依照PRISMA指南进行。
- 共纳入24项研究、1820例患者,其中11篇为全文手稿。
主要发现
- 24项研究中DAA治疗后肝细胞癌复发比例范围为0%至59%,汇总估计为24.4%(95%CI:18.4%-30.4%)。
- 11篇全文手稿中汇总肝细胞癌复发率为21.9%(95%CI:16.2%-28.3%)。
- 与复发相关的因素包括既往肝细胞癌复发史以及肝细胞癌完全缓解与启动DAA之间间隔较短。
- 9项比较DAA治疗与干扰素治疗或未治疗患者的研究发现DAA治疗患者复发率相似。
- 多数(77.8%)复发患者发现时处于早期肿瘤阶段,其中64.7%接受了治愈性治疗。
关键数值与推荐
- 24项研究汇总肝细胞癌复发率为24.4%(95%CI:18.4%-30.4%)。
- 11篇全文手稿汇总肝细胞癌复发率为21.9%(95%CI:16.2%-28.3%)。
- DAA治疗后肝细胞癌复发比例范围为0%至59%。
- 复发患者中77.8%发现时处于早期肿瘤阶段,其中64.7%接受了治愈性治疗。
临床怎么用
- 原文结论提示DAA治疗后肝细胞癌复发率可接受,尤其若在肝细胞癌完全缓解后至少延迟6个月再启动DAA治疗。
- 原文未据此给出其他具体临床推荐。
局限性
- 研究局限性包括队列异质性。
- 研究局限性包括DAA治疗前无肝细胞癌状态可能存在错误分类。
- 研究局限性包括复发确认偏倚。
- 研究局限性包括随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although studies suggest decreased incident hepatocellular carcinoma (HCC) after direct-acting antivirals (DAA), data are conflicting regarding HCC recurrence and aggressiveness in patients who have a history of HCC with complete response. AIM: Characterize HCC recurrence patterns after DAA therapy. METHODS: Two reviewers searched MEDLINE and SCOPUS from January 2015 to December 2017 and identified studies evaluating HCC recurrence patterns following DAA therapy. A pooled estimate was calculated using the DerSimonian and Laird method for a random effects model. The study was conducted in accordance with PRISMA guidelines. RESULTS: Among 24 studies (n = 1820 patients), the proportion of patients with HCC recurrence following DAA therapy ranged from 0% to 59% (pooled estimate 24.4%; 95% CI: 18.4%-30.4%). Among 11 full text manuscripts, pooled HCC recurrence was 21.9% (95% CI: 16.2%-28.3%). Factors associated with recurrence included history of prior HCC recurrence and a shorter interval between HCC complete response and DAA initiation. Nine studies comparing DAA-treated and interferon-treated or untreated patients found similar recurrence among DAA-treated patients. Most (77.8%) patients with HCC recurrence were detected at an early tumour stage, of whom 64.7% received curative treatment. Study limitations included heterogeneous cohorts, potential misclassification of HCC absence prior to DAA, ascertainment bias for recurrence, and short durations of follow-up. CONCLUSIONS: Current data suggest acceptable HCC recurrence rates after DAA therapy, particularly if DAA therapy is delayed at least 6 months after HCC complete response. However, data characterising HCC recurrence after DAA therapy are of limited quality, highlighting the need for high quality prospective studies.
引用
- Saraiya N, Yopp AC, Rich NE, et al. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018. PMID: 29851093. doi:10.1111/apt.14823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。